Patent application number | Description | Published |
20100255012 | RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications. | 10-07-2010 |
20100267934 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 10-21-2010 |
20100291023 | METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES - The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule. | 11-18-2010 |
20100306867 | TRANSGENIC ANIMALS PRODUCING MONOVALENT HUMAN ANTIBODIES AND ANTIBODIES OBTAINABLE FROM THESE ANIMALS - The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods. | 12-02-2010 |
20100325744 | NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES - The present invention provides non-glycosylated monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies. | 12-23-2010 |
20110045007 | FUSION OR LINKED PROTEINS WITH EXTENDED HALF LIFE - The present invention provides fusion proteins comprising a first molecule, and a second molecule which is a monovalent immunoglobulin or a fragment of a monovalent immunoglobulin with a long half-life when administered in vivo, methods of making such fusion proteins, pharmaceutical compositions comprising such fusion proteins, and uses thereof. | 02-24-2011 |
20110086366 | METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES - The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies. | 04-14-2011 |
20110293607 | Antibody Variants Having Modifications In The Constant Region - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 12-01-2011 |
20120020952 | METHODS FOR PRODUCING MIXTURES OF ANTIBODIES - The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention. | 01-26-2012 |
20130039913 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. | 02-14-2013 |
20130189271 | MONOCLONAL ANTIBODIES AGAINST HER2 - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 07-25-2013 |
20130216548 | MONOCLONAL ANTIBODIES AGAINST C-MET - Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 08-22-2013 |
20130345406 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 12-26-2013 |
20140170148 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140170149 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140242075 | ANTIBODY VARIANTS AND USES THEREOF - Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response. | 08-28-2014 |
20140303356 | PRODUCTION OF HETERODIMERIC PROTEINS - The present invention relates to an in vitro method for production of heterodimeric proteins. | 10-09-2014 |